Raising the bar in myopia control

MiYOSMART iQ

Raising the bar in myopia control

9 out of 10 children showed no clinically relevant myopia progression* in the first 12 months of wear1,2  

HOYA’s most advanced myopia control spectacle lens marks a new era for D.I.M.S. Technology by combining it with a new Triple Enhanced Design (DIMS TED), delivering stronger outcomes for children who need more.

Science behind MiYOSMART iQ

Building on the proven foundation of D.I.M.S. Technology, MiYOSMART iQ introduces a more advanced approach to myopia control.

 

Triple Enhanced Design (TED)

Three critical design enhancements have been introduced to improve myopia control performance. Elevated with the Triple Enhanced Design, D.I.M.S. Technology features include:

  • Activated -Defocus segments closer to the center to continuously activate the near-peripheral retina identified as the region most responsive to myopic defocus.5,6
  • Powerful -Higher defocus power, enabling a stronger myopic defocus signal to the near-peripheral retina.
  • Extended -Larger treatment zone to ensure extensive coverage of the child's peripheral visual field with myopic defocus signal, even for larger frames.

MiYOSMART just got smarter

Continuous activation of the "Smart Zone"*

The near-peripheral retina was found to be highly responsive to myopic defocus signals and can play a pivotal role in regulating eye growth mechanisms, influencing long-term refractive development.4,5

Designed to activate. Continuously.

The DIMS TED spectacle lens, due to its smarter design, intends to continuously activate the "Smart Zone", maximizing myopia control effectiveness.

*”Smart Zone” is a marketing term used by HOYA when referring to a near-peripheral retinal zone shown to respond to myopic defocus. It is not a standard clinical or scientific term.

A breakthrough in clinical performance

MiYOSMART iQ delivers the strongest clinical results to date for D.I.M.S. Technology and has been evaluated in a randomised controlled controlled clinical trial (RCT) in children aged 4 to 12 years.6,7

These outcomes represent the most effective myopia control results seen so far with D.I.M.S. Technology spectacle lenses.

→ 9 out of 10 children showed no clinically relevant myopia progression at 12 months1-3

→ Minimal eye growth on average in the first 12 months of wear*1,2

→ HOYA's first spectacle lens with reported clinical evidence for effective control of myopia progression from the age of 4 years, as a monotherapy.1-3

"DIMS TED produced the strongest normalization effect, with axial elongation not merely approaching but falling below the AMMC-defined physiological growth range, effectively neutralizing myopic axial growth in the past."

Prof. Hakan Kaymak

Professor of Universität des Saarlandes and leading researcher at the Internationale Innovative Ophthalmochirurgie in Düsseldorf, Germany

Optimized aspherical backside design

MiYOSMART iQ spectacle lenses are now available with an optimized aspherical backside design, taking optical quality to the next level.

Enhanced clarity

Using FreeForm technology, prescription values are optimized on the back surface of the lens to ensure superior visual performance in everyday viewing situations, no matter where children look.

MiYOSMART iQTF optical design is engineered to reduce optical aberrations, offering sharper image quality and clear vision across the lens.

Refined aesthetics

How spectacles look and feel truly matters to children8, especially when their prescriptions increase. MiYOSMART iQTF spectacle lenses are designed with flatter lens curvatures, improving lens aesthetics by reducing edge thickness.

With an edge thickness reduced by up to 10% compared to a standard spectacle lens9, MiYOSMART iQTF offers improved frame compatibility and a more aesthetic appearance.

Advanced performance. Two ways.

Designed to fit seamlessly into daily life.

MiYOSMART iQ Clear

Clinically proven, optically excellent, and indistinguishable from a regular corrective lens.

MiYOSMART iQ Chameleon

Adaptive tinting for children who spend time both indoors and outdoors, offering the same advanced myopia control with additional UV protection and visual comfort in changing light conditions.  

MiYOSMART iQ with S.P.A.R.K Coating

Introducing S.P.A.R.K., our advanced protective coating for MiYOSMART iQ spectacle lenses. This new protective coating is Scratch resistant, gives them the Protection they need, uses Advanced technologies and is Ready for Kids (S.P.A.R.K.). Built with kids in mind, tailored for the long run.

Enhanced scratch resistance

50% more scratch-resistant than the previous generation,10 helping protect lenses from everyday wear and handling.  

Resistance to smudges, dust, and water

Repels fingerprints and dust, while offering water resistance five times greater than the previous MiYOSMART generation.10,11  

Long-lasting cleanability

Designed to maintain easy-to-clean performance, even after nearly 3 years of daily wiping.10,11

Clear, comfortable vision

Supports high light transmission while reducing glare and reflections for consistent visual clarity.12

UV protection 

Blocks 100%11 of harmful UV rays from the front surface and helps reduce UV exposure from the back of the lens.  

Supporting you at every step

MiYOSMART iQ supports both the child and the Eye Care Professional. A streamlined clinical workflow and dedicated tools make integration into your practice simple.

Step 1

Assessment: Any child with progressing myopia from age 4, including those with an inadequate control on existing myopia management treatment.

 

Step 2

Fitting: Ensure optimal centration for maximum treatment effectiveness with the visuReal MoveAI Kids Module, HOYA’s AI-powered centration tool specifically developed for paediatric myopia management lenses. Confirm frame size compatibility — the extended 41mm treatment zone supports a wide range of children’s frames.

Step 3

Follow-up: Schedule follow-up within 6 months. Monitor axial length and myopia progression. Use results to reinforce compliance and guide discussions with parents.

 

 

HOYA provides training, webinars, and clinical resources to support confident prescribing. Contact your HOYA representative for access to the full MiYOSMART iQ professional toolkit.  

MiYOSMART iQ redefines what is possible

Let's raise the bar in myopia control

Keeping in the Know

The Latest News from MiYOSMART

The outstanding products and excellence in service

At HOYA, we are ready to answer any questions you might have, explore our potential partnership and hear the ideas you want to share with us. Get in touch with us by completing the form below.

Get in touch About HOYA

Disclaimer

MiYOSMART iQ has not been approved for myopia control in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.

MiYOSMART spectacle lenses may not be able to address individuals’ conditions due to natural deficiencies, illness, pre-existing medical conditions and/or advanced age of consumers. The information contained herein is general information and is not intended to constitute medical advice.

This information includes recommendations for Eye Care Professionals. The Eye Care Professional is responsible for ensuring that the recommended procedure is allowed to be conducted in the country where they practice. Suitability of each recommended procedure for individual patients should be evaluated by the Eye Care Professional based on their professional judgment.

*Clinically relevant myopia progression defined as Spherical Equivalent Refraction change equal to or superior to -0.50D over 12 months of wear. Outcomes for myopic children aged 4 to 12 years. They may vary per age group and other parameters at the start of MiYOSMART iQ treatment.

References

(1) Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D. K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA. https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941 (accessed date 03.04.2026)

 

(2) HOYA data on file. HOYA MiYOSMART iQ spectacle lens clinical outcomes. 04/2026.

 

(3) Based on the number of publications in peer-reviewed publications according to HOYA’s data on file as of Nov 25.

 

(4) HOYA data on file. MiYOSMART spectacle lens commercial data. 04/2026.

 

(5) Smith III EL, Arumugam B, Hung LF, et al. Eccentricity-dependent effects of simultaneous competing defocus on emmetropization in infant rhesus monkeys. Vision Res. 2020;177:32-40. DOI: 10.1016/j.visres.2020.08.003.

 

(6) Swiatczak B, Scholl HPN, Schaeffel F. Retinal ‘sweet spot’ for myopia treatment. Sci Rep 14, 26773 (2024). https://doi.org/10.1038/s41598-024-78300-x

 

(7) Tse DYY, Chun RKM, Hon Y, et al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Triple Enhanced Design Spectacle Lenses. The 41st Asia-Pacific Academy of Ophthalmology Congress, 2026. https://2026.apaophth.org/abstract/?code=205567. Accessed 12 Jan 2026. Peer-reviewed publication will follow.

 

(8) Eyewear Market Size, Share & Trends Analysis Report.” Grand View Research, 2025, https://www.grandviewresearch.com/industry-analysis/eyewear-industry [Accessed 24 Apr. 2026].

 

(9) HOYA data on file. 04/2026. All edge reduction percentages are calculated at a 65 mm diameter, comparing spherical and aspheric designs, with a maximum value of 10%. (Without providing edge thickness values.)

 

(10) HOYA data on file. MiYOSMART iQ S.P.A.R.K. coating technical results. 05/2026.

 

(11) HOYA data on file. Product assessment report – “STX MiYOSMART Green PAR. 06/2025.

 

(12) HOYA data on file. MiYOSMART iQ S.P.A.R.K. coating technical data. 04/2026. Compliance with ISO 8980-3:2022.